SEC Form 4 · accession 0001209191-18-024356
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen A. Tullman
Director
Period of report
Apr 6, 2018
Accepted (ET)
Apr 9, 2018 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Apr 6, 2018 | P | 26,700 | $16.54 | A | 157,507 | D | |
| Common StockF3 | holding | — | — | — | 394,014 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $16.23 to $17.06, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F3These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which the reporting person's spouse serves as the trustee.